Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$1.44
-5.9%
$1.83
$1.39
▼
$4.06
$87.93M3.48913,851 shs645,968 shs
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
$8.65
+20.1%
$8.84
$3.70
▼
$23.00
$29.91M0.47172,293 shs50,728 shs
Genelux Corporation stock logo
GNLX
Genelux
$2.00
+4.2%
$2.29
$1.77
▼
$5.89
$86.87M0.68423,618 shs251,279 shs
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$0.40
+0.3%
$0.58
$0.30
▼
$1.63
$80.85M1.1912.97 million shs2.14 million shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-5.88%-9.72%-16.28%-34.25%-64.09%
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
+20.14%+68.62%+43.93%-27.14%-22.87%
Genelux Corporation stock logo
GNLX
Genelux
+4.17%+2.56%-17.36%-25.37%-61.90%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
+0.30%-0.25%-16.53%-60.50%-62.71%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$1.44
-5.9%
$1.83
$1.39
▼
$4.06
$87.93M3.48913,851 shs645,968 shs
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
$8.65
+20.1%
$8.84
$3.70
▼
$23.00
$29.91M0.47172,293 shs50,728 shs
Genelux Corporation stock logo
GNLX
Genelux
$2.00
+4.2%
$2.29
$1.77
▼
$5.89
$86.87M0.68423,618 shs251,279 shs
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$0.40
+0.3%
$0.58
$0.30
▼
$1.63
$80.85M1.1912.97 million shs2.14 million shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-5.88%-9.72%-16.28%-34.25%-64.09%
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
+20.14%+68.62%+43.93%-27.14%-22.87%
Genelux Corporation stock logo
GNLX
Genelux
+4.17%+2.56%-17.36%-25.37%-61.90%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
+0.30%-0.25%-16.53%-60.50%-62.71%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
2.60
Moderate Buy$11.00663.89% Upside
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
1.00
SellN/AN/A
Genelux Corporation stock logo
GNLX
Genelux
2.75
Moderate Buy$20.00900.00% Upside
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
2.60
Moderate Buy$4.19949.50% Upside

Current Analyst Ratings Breakdown

Latest BKHA, BDTX, GNLX, and LUCD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Reiterated RatingSell (E+)
11/12/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Reiterated RatingBuy
11/10/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Reiterated RatingOutperform
10/29/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Reiterated RatingBuy
10/23/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Reiterated RatingBuy
10/15/2026
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
Reiterated RatingSell (D)
10/15/2026
Genelux Corporation stock logo
GNLX
Genelux
Reiterated RatingSell (E+)
10/9/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Reiterated RatingSell (D-)
10/1/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Reiterated RatingBuy
9/16/2026
Genelux Corporation stock logo
GNLX
Genelux
UpgradeStrong-Buy
8/18/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$70M1.18$0.50 per share2.90$1.53 per share0.94
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/AN/AN/AN/A
Genelux Corporation stock logo
GNLX
Genelux
$10K9,048.00N/AN/A$0.30 per share6.67
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$4.71M17.22N/AN/A$0.03 per share13.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$22.37M-$0.77N/AN/AN/AN/A-36.66%-28.44%N/A
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Genelux Corporation stock logo
GNLX
Genelux
-$32.15M-$0.86N/AN/AN/AN/A-224.99%-146.63%11/18/2026 (Estimated)
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-$58.01M-$0.40N/AN/AN/A-892.75%N/A-142.71%N/A

Latest BKHA, BDTX, GNLX, and LUCD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q3 2026
Genelux Corporation stock logo
GNLX
Genelux
-$0.1983-$0.23-$0.0317-$0.23N/AN/A
11/12/2026Q3 2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-$0.0575-$0.06-$0.0025-$0.03$1.63 million$1.20 million
11/10/2026Q3 2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-$0.0938-$0.17-$0.0763-$0.17$8.33 millionN/A
10/6/2026Q3 2026
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A$0.26N/A$0.26N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/AN/AN/AN/AN/A
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/AN/AN/A
Genelux Corporation stock logo
GNLX
Genelux
N/AN/AN/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/A
6.92
6.92
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/A
Genelux Corporation stock logo
GNLX
Genelux
N/A
2.39
2.39
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
N/A
1.20
1.18

Institutional Ownership

CompanyInstitutional Ownership
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
95.47%
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A
Genelux Corporation stock logo
GNLX
Genelux
37.33%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
74.01%

Insider Ownership

CompanyInsider Ownership
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
9.29%
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A
Genelux Corporation stock logo
GNLX
Genelux
7.50%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
2157.47 million52.13 millionOptionable
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
24.15 millionN/AN/A
Genelux Corporation stock logo
GNLX
Genelux
2645.24 million41.85 millionOptionable
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
82203.24 million189.22 millionNo Data

Recent News About These Companies

Lucid Diagnostics' (LUCD) "Buy" Rating Reiterated at BTIG Research
Lucid Diagnostics (LUCD) Q3 2026 Earnings Call Transcript
Lucid Diagnostics Analyst Price Targets

New MarketBeat Followers Over Time

Media Sentiment Over Time

Black Diamond Therapeutics stock logo

Black Diamond Therapeutics NASDAQ:BDTX

$1.44 -0.09 (-5.88%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$1.46 +0.02 (+1.04%)
As of 11/17/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Black Hawk Acquisition stock logo

Black Hawk Acquisition NASDAQ:BKHA

$8.65 +1.45 (+20.14%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$7.72 -0.93 (-10.69%)
As of 11/17/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Black Hawk Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2023 and is based in Danville, California.

Genelux stock logo

Genelux NASDAQ:GNLX

$2.00 +0.08 (+4.17%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$2.03 +0.03 (+1.70%)
As of 11/17/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Lucid Diagnostics stock logo

Lucid Diagnostics NASDAQ:LUCD

$0.40 +0.00 (+0.30%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.39 -0.01 (-2.76%)
As of 11/17/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.